KR20030019389A - 점막감염의 치료 조성물 및 방법 - Google Patents
점막감염의 치료 조성물 및 방법 Download PDFInfo
- Publication number
- KR20030019389A KR20030019389A KR1020027015631A KR20027015631A KR20030019389A KR 20030019389 A KR20030019389 A KR 20030019389A KR 1020027015631 A KR1020027015631 A KR 1020027015631A KR 20027015631 A KR20027015631 A KR 20027015631A KR 20030019389 A KR20030019389 A KR 20030019389A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- adjuvant
- microorganism
- bacteria
- nthi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title claims abstract description 10
- 206010065764 Mucosal infection Diseases 0.000 title claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims abstract description 21
- 229960005486 vaccine Drugs 0.000 claims abstract description 19
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 7
- 241000894006 Bacteria Species 0.000 claims description 59
- 239000002671 adjuvant Substances 0.000 claims description 37
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 34
- 244000005700 microbiome Species 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 11
- 210000004877 mucosa Anatomy 0.000 claims description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 241000606768 Haemophilus influenzae Species 0.000 claims description 5
- 241000187644 Mycobacterium vaccae Species 0.000 claims description 5
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 4
- 230000024932 T cell mediated immunity Effects 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 4
- 241000186359 Mycobacterium Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 230000036755 cellular response Effects 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 244000053095 fungal pathogen Species 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims 2
- 241000194036 Lactococcus Species 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 229940126578 oral vaccine Drugs 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 46
- 239000002953 phosphate buffered saline Substances 0.000 description 44
- 210000004072 lung Anatomy 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 230000004044 response Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000007330 chocolate agar Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000035611 feeding Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000008881 mucosal defense Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 102100031102 C-C motif chemokine 4 Human genes 0.000 description 1
- 101100054773 Caenorhabditis elegans act-2 gene Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ7612 | 2000-05-19 | ||
| AUPQ7612A AUPQ761200A0 (en) | 2000-05-19 | 2000-05-19 | Compositions and methods for treatment of mucosal infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20030019389A true KR20030019389A (ko) | 2003-03-06 |
Family
ID=3821690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027015631A Withdrawn KR20030019389A (ko) | 2000-05-19 | 2001-05-21 | 점막감염의 치료 조성물 및 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8637051B2 (https=) |
| EP (1) | EP1305042B1 (https=) |
| JP (2) | JP5567756B2 (https=) |
| KR (1) | KR20030019389A (https=) |
| CN (1) | CN1437480A (https=) |
| AT (1) | ATE535284T1 (https=) |
| AU (1) | AUPQ761200A0 (https=) |
| BR (1) | BR0110971A (https=) |
| CA (1) | CA2409813C (https=) |
| WO (1) | WO2001087332A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ761200A0 (en) * | 2000-05-19 | 2000-06-15 | Hunter Immunology Limited | Compositions and methods for treatment of mucosal infections |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| TWI350174B (en) * | 2003-03-12 | 2011-10-11 | Wyeth Corp | Adjuvanted bovine vaccines |
| WO2005077409A1 (en) * | 2004-02-18 | 2005-08-25 | The University Of Newcastle Research Associates Limited | A vaccine formulated for administration to mucosa of the lungs |
| US7862808B2 (en) | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
| CA2577165C (en) * | 2004-08-17 | 2015-01-27 | Hunter Immunology Pty Limited | Oral killed vaccines and method for providing same |
| US20070269376A1 (en) * | 2004-08-17 | 2007-11-22 | Hunter Immunology Limited | Method for Determining Dosage for an Oral Killed Vaccine |
| US7303745B2 (en) * | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
| US20060233762A1 (en) * | 2005-04-15 | 2006-10-19 | Mcmahon Robert J | Method for treating or preventing systemic inflammation in formula-fed infants |
| WO2011115762A1 (en) | 2010-03-18 | 2011-09-22 | Eveready Battery Company, Inc. | Button cell battery dispenser package |
| EP2585094B1 (en) * | 2010-06-25 | 2018-08-01 | INSERM - Institut National de la Santé et de la Recherche Médicale | Flagellin polypeptide as tlr5 agonist for use in the treatment of respiratory tract infections |
| WO2013028756A1 (en) | 2011-08-22 | 2013-02-28 | Carnegie Mellon University | Atom transfer radical polymerization under biologically compatible conditions |
| JP6632607B2 (ja) * | 2014-05-02 | 2020-01-22 | クー バイオロジックス インク．Ｑｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． | 抗微生物免疫修飾 |
| US9982070B2 (en) | 2015-01-12 | 2018-05-29 | Carnegie Mellon University | Aqueous ATRP in the presence of an activator regenerator |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| EP4132478A1 (en) | 2020-04-09 | 2023-02-15 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| CN111529703B (zh) * | 2020-06-17 | 2023-09-15 | 湖南循天然营养有限公司 | 一种组合物及其制备方法与在制备免疫佐剂中的应用 |
| WO2024234034A1 (en) * | 2023-05-12 | 2024-11-21 | Biomune Pty Ltd | Compositions and methods for preventative treatments for mucosal associated ailments |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA907737B (en) * | 1989-09-29 | 1991-07-31 | Nisshin Oil Mills Ltd | Stable immunogen composition for oral administration |
| US6231870B1 (en) * | 1995-06-02 | 2001-05-15 | Uab Research Foundation | Oral administration of pneumoccal antigens |
| JPH0680575A (ja) * | 1991-03-05 | 1994-03-22 | Meiji Milk Prod Co Ltd | 経口免疫賦活剤 |
| AU724743B2 (en) * | 1996-05-31 | 2000-09-28 | Genetics Institute, Llc | IL-12 as an adjuvant for Bordetella Pertussis vaccines |
| WO1998056415A1 (en) | 1997-06-11 | 1998-12-17 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| US6287568B1 (en) | 1997-09-09 | 2001-09-11 | The Trustees Of Columbia University In The City Of New York | Methods relating to immunogenic dextran-protein conjugates |
| US6153182A (en) * | 1997-12-19 | 2000-11-28 | Uab Research Foundation | Lymphotactin as an adjuvant |
| EP1044273A2 (en) | 1997-12-23 | 2000-10-18 | Genesis Research & Development Corporation Limited | COMPOSITIONS DERIVED FROM $i(MYCOBACTERIUM VACCAE) AND METHODS FOR THEIR USE |
| GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| GB9801870D0 (en) * | 1998-01-28 | 1998-03-25 | Raby Limited | Vaccine composition |
| PT1053325E (pt) * | 1998-02-05 | 2006-05-31 | Glaxosmithkline Biolog Sa | Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao. |
| SE9800615D0 (sv) * | 1998-02-27 | 1998-02-27 | Ingvar Sjoeholm | Mucosal microparticle conjugate vaccine |
| JP2002505302A (ja) * | 1998-03-05 | 2002-02-19 | ザ メディカル カレッジ オブ オハイオ | Ｉｌ−１２の鼻腔内イノキュレーションによる免疫の増強 |
| US5985264A (en) * | 1998-03-05 | 1999-11-16 | The Medical College Of Ohio | IL-12 Stimulation of Neonatal immunity |
| FR2776521B1 (fr) * | 1998-03-27 | 2000-12-15 | Pf Medicament | Utilisation de conjugues p40 actifs par voie nasale |
| WO2000000218A1 (fr) * | 1998-06-26 | 2000-01-06 | Aventis Pasteur | Immunisation a ciblage mucosal |
| AR020102A1 (es) * | 1998-07-30 | 2002-04-10 | Ucb Sa | Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento |
| GB9909077D0 (en) | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
| US7223398B1 (en) * | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| US20020044926A1 (en) * | 1999-12-10 | 2002-04-18 | Gregor Reid | Oral administration of lactobacillus for the treatment and prevention of urogenital infection |
| AUPQ761200A0 (en) * | 2000-05-19 | 2000-06-15 | Hunter Immunology Limited | Compositions and methods for treatment of mucosal infections |
| DE60142786D1 (de) * | 2000-06-19 | 2010-09-23 | Hunter Immunology Ltd | Zusammensetzungen und methoden zur behandlung von candidosen |
| EP1311684A4 (en) * | 2000-08-08 | 2005-10-19 | Genesis Res & Dev Corp Ltd | LACTOBACILLUS RHAMNOSUS POLYNUCLEOTIDES, POLYPEPTIDES, AND METHODS FOR THEIR USE |
-
2000
- 2000-05-19 AU AUPQ7612A patent/AUPQ761200A0/en not_active Abandoned
-
2001
- 2001-05-21 AT AT01931225T patent/ATE535284T1/de active
- 2001-05-21 CA CA2409813A patent/CA2409813C/en not_active Expired - Lifetime
- 2001-05-21 EP EP01931225A patent/EP1305042B1/en not_active Expired - Lifetime
- 2001-05-21 KR KR1020027015631A patent/KR20030019389A/ko not_active Withdrawn
- 2001-05-21 CN CN01811367A patent/CN1437480A/zh active Pending
- 2001-05-21 US US10/276,829 patent/US8637051B2/en not_active Expired - Fee Related
- 2001-05-21 WO PCT/AU2001/000588 patent/WO2001087332A1/en not_active Ceased
- 2001-05-21 BR BR0110971-5A patent/BR0110971A/pt not_active Application Discontinuation
- 2001-05-21 JP JP2001583799A patent/JP5567756B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-30 JP JP2012080832A patent/JP2012153706A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP5567756B2 (ja) | 2014-08-06 |
| CA2409813C (en) | 2013-11-12 |
| EP1305042B1 (en) | 2011-11-30 |
| ATE535284T1 (de) | 2011-12-15 |
| US20040057965A1 (en) | 2004-03-25 |
| WO2001087332A1 (en) | 2001-11-22 |
| JP2012153706A (ja) | 2012-08-16 |
| EP1305042A4 (en) | 2005-02-02 |
| CA2409813A1 (en) | 2001-11-22 |
| EP1305042A1 (en) | 2003-05-02 |
| AUPQ761200A0 (en) | 2000-06-15 |
| US8637051B2 (en) | 2014-01-28 |
| CN1437480A (zh) | 2003-08-20 |
| BR0110971A (pt) | 2005-04-05 |
| JP2003533489A (ja) | 2003-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012153706A (ja) | 粘膜感染症の処置のための組成物および方法 | |
| Montero et al. | Vibrio cholerae, classification, pathogenesis, immune response, and trends in vaccine development | |
| Matsuzaki et al. | Modulating immune responses with probiotic bacteria | |
| US20030180260A1 (en) | Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor | |
| Silin et al. | Oral vaccination: where we are? | |
| JP2014512388A (ja) | 免疫反応を増進するための組成物および方法 | |
| JP3919812B2 (ja) | Ｈ．ピロリ関連胃十二指腸疾患の治療 | |
| Russell et al. | Overview: the mucosal immune system | |
| WO2008053055A1 (es) | Vacuna profiláctica contra la tuberculosis | |
| Jayanthi et al. | Bacillus clausii-The probiotic of choice in the treatment of diarrhoea | |
| JP2007169200A (ja) | インフルエンザ感染予防のための医薬及び飲食品 | |
| De Moreno de LeBlanc et al. | Oral administration of L. casei CRL 431 increases immunity in bronchus and mammary glands | |
| AU2001258060B2 (en) | Compositions and methods for treatment of mucosal infections | |
| EP1725256A1 (en) | A vaccine formulated for administration to mucosa of the lungs | |
| AU2001258060A1 (en) | Compositions and methods for treatment of mucosal infections | |
| Das et al. | A prophylactic study of curcumin nanoparticle-induced bacterial ghosts against Helicobacter pylori in a C57BL/6 mouse model | |
| Singh et al. | Salmonella Typhi: Virulence, Multi drug Resistance and Vaccines | |
| Stelmasiak et al. | Mechanisms of action and expected clinical effects of modulation of the MALT system by oral bacterial lyophylisates | |
| Kroeker et al. | Treatment of Ulcerative Colitis | |
| Germani et al. | Live-Attenuated Shigella Vaccines. Is Encouraging Good Enough? | |
| US20240366755A1 (en) | Methods of use & compositions of ibd, ibs, & antineoplasticmicrobial therapeutics | |
| Woo et al. | Enhancement of humoral and protective immune response induced by live‐attenuated Salmonella typhi by ampicillin | |
| Holder et al. | Oral Pseudomonas aeruginosa immunization enhances survival in mice subsequently burned and infected with P. aeruginosa | |
| Goswami et al. | TB Vaccine: Current Scenario and Future Possibilities | |
| Buck | Vaccine therapy for chronic Helicobacter infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20021119 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |